Oricell Therapeutics closed a $110 million pre-IPO financing to broaden its pipeline of solid-tumor cell therapies, with a focus on its GPC3-targeted autologous CAR-T program for hepatocellular carcinoma. The company said the funding is intended to support expansion and progression toward registrational trials. The lead asset, Ori-C101, has completed early human testing, including investigator-initiated studies and a registrational-phase 1 effort that reported responses at higher dose levels. Oricell framed the program as aiming for broader global clinical development with the goal of a potential first-in-class option in HCC. The round also highlights the continued push into solid tumors for CAR-T approaches, particularly where antigen expression heterogeneity and immune suppression complicate targeting. Oricell’s portfolio includes additional named candidates, including a Phase 1/2 program in multiple myeloma. The financing adds to a wider resurgence in biopharma funding for late preclinical-to-clinical innovation, while reinforcing investor appetite for differentiated cell-therapy platforms.